Phio Pharmaceuticals Corp.
PHIO
$1.09
$0.010.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 83.39% | 24.02% | -22.82% | -2.18% | -64.38% |
| Gross Profit | -83.39% | -24.02% | 22.82% | 2.18% | 64.38% |
| SG&A Expenses | 39.96% | 17.84% | -7.07% | -10.05% | -2.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.55% | 20.64% | -15.26% | -5.58% | -42.72% |
| Operating Income | -57.55% | -20.64% | 15.26% | 5.58% | 42.72% |
| Income Before Tax | -56.96% | -17.33% | 17.87% | 14.20% | 45.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.96% | -17.33% | 17.87% | 14.20% | 45.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.96% | -17.33% | 17.87% | 14.20% | 45.18% |
| EBIT | -57.55% | -20.64% | 15.26% | 5.58% | 42.72% |
| EBITDA | -57.50% | -20.67% | 15.24% | 5.05% | 42.41% |
| EPS Basic | 71.58% | 87.52% | 90.30% | 74.77% | 84.99% |
| Normalized Basic EPS | 71.58% | 87.52% | 90.30% | 72.98% | 84.99% |
| EPS Diluted | 71.58% | 87.52% | 90.30% | 74.77% | 84.99% |
| Normalized Diluted EPS | 71.58% | 87.52% | 90.30% | 72.98% | 84.99% |
| Average Basic Shares Outstanding | 452.38% | 839.81% | 746.39% | 240.07% | 265.18% |
| Average Diluted Shares Outstanding | 452.38% | 839.81% | 746.39% | 240.07% | 265.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |